Vimta Labs Limited — Investor Meet, 12-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Vimta Labs posted strong Q4 & FY26 results. Q4 revenue rose 16.6% YoY to INR 112 Cr, EBITDA jumped 21.5% to INR 42.1 Cr (37.6% margin), and PAT grew 15.2% to INR 21.1 Cr. FY26 revenue was up 19.5% to INR 416.3 Cr, with 35.8% EBITDA margins. Pharma & Food divisions powered growth.

The company is net debt-free with INR 65 Cr cash. Management aims for continued 20-25% CAGR growth and sees biologics contract research as a key future driver, initially focusing on client acquisition. Global uncertainties pose headwinds, but Vimta remains confident in its long-term strategy and robust demand from diverse sectors.